Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 26, Issue 8, Pages E177-E182Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2020.04.013
Keywords
Hematopoietic cell transplantation; Activity; Summary slides
Categories
Funding
- Public Health Service [U24CA076518]
- National Cancer Institute (NCI) the National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID) [U24HL138660]
- NHLBI [OT3HL147741, R21HL140314, K23HL141445, U01HL128568, R01 HL131731, R01 HL126589]
- NCI [U24CA233032, 5R01 CA2151343]
- Health Resources and Services Administration (HRSA) [HHSH250201700006C]
- Office of Naval Research [N00014-18-1-2888, N00014-17-1-2850, N00014-20-1-2705]
- Biomedical Advanced Research and Development Authority Grant [HHS0100201800012C]
- HRSA [SC1MC31881-01-00]
- NIH [R01 HL131731, R01 HL126589, P01 CA111412, R01 CA152108, R01 CA218285, R01 CA231141, R01 HL129472, U01 AI126612]
- AbbVie
- Actinium Pharmaceuticals
- Adaptive Biotechnologies
- Adienne
- Allovir
- Amgen
- Anthem
- Astellas Pharma US
- Atara Biotherapeutics
- bluebird bio
- Bristol Myers Squibb
- Celgene
- Chimerix
- CSL Behring
- CytoSen Therapeutics
- Daiichi Sankyo
- DanaFarber Cancer Institute
- Enterprise Science and Computing
- Gamida Cell
- Genzyme
- GlaxoSmithKline
- HistoGenetics
- Immune Deficiency Foundation
- Incyte
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Research Development
- Jazz Pharmaceuticals
- Kiadis Pharma
- Kite Pharma
- Kyowa Kirin
- Magenta Therapeutics
- Medac
- Merck Company
- Merck Sharp Dohme
- Mesoblast
- Millennium
- Miltenyi Biotec
- Montefiore Medical Center
- Novartis Oncology
- Novartis Pharmaceuticals
- Omeros
- Oncoimmune
- Orca Biosystems
- Pfizer
- Phamacyclics
- Regeneron Pharmaceuticals
- REGiMMUNE
- Sanofi Genzyme
- Seattle Genetics
- Shire
- Sobi
- Takeda Oncology
- Takeda Pharma
- Viracor Eurofins
- Xenikos BV
- Be the Match Foundation
- National Marrow Donor Program
- St Baldrick's Foundation
- Medical College of Wisconsin
Ask authors/readers for more resources
Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States. (C) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available